Artherogenesis - Recent insights into basic mechanisms and their clinical impact

Nephrology Dialysis Transplantation

Volumn 17, Issue 12, 2002, Pages 2055-2064

  Scächinger, Volger ^a   Zeiher, Andreas M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; APYRASE; ATENOLOL; C REACTIVE PROTEIN; CD39 ANTIGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLUTAMINE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTACYCLIN; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SEROTONIN; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; GENE THERAPY; HEART PROTECTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; ARTERIOSCLEROSIS; DRUG EFFECT; METABOLISM; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; PROGNOSIS; VASODILATION;

EID: 0036900289     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999; 31: 5-14
2. Britten MB, Zeiher AM, Schächinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245: 315-328
3. Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by AKT-dependent phosphorylation. Nature 1999; 399: 601-605
4. Moncada S, Hill JA. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012
5. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844
7. Oskarsson HJ, Heistad DD. Oxidative stress produced by angiotensin too. Implications for hypertension and vascular injury. Circulation 1997; 95: 557-559
8. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-2551
9. Channon KM, Qian H, George SE. Nitric oxide synthase in atherosclerosis and vascular injury: insights from experimental gene therapy. Arterioscler Thromb Vasc Biol 2000; 20: 1873-1881
10. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000; 20: 1430-1442
11. Schultz D, Harrison DG. Quest for fire: seeking the source of pathogenic oxygen radicals in atherosclerosis [Editorial]. Arterioscler Thromb Vasc Biol 2000; 20: 1412-1413
12. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157
13. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037
14. Minor RLJ, Myers PR, Guerra RJ et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-2116
15. Wilcox JN, Subramanian RR, Sundell CL et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-2488
16. Wever RM, Lüscher TF, Cosentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112
17. Fichtlscherer S, Rosenberger G, Walter DH et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006
18. Fichtlscherer S, Rosenberger G, Zeiher AM. Evidence for enhanced systemic oxidative stress in patients with acute coronary syndrome. Circulation 1999; 100: I-756.
19. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation 1999; 100: 1148-1150
20. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001; 358: 946-948
21. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168
22. Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102
23. Torzewski M, Rist C, Mortensen RF et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 2094-2099
24. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182
25. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155
26. Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232
27. Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375
28. Langille BL, O'Donnell F. Reduction of arterial diameter produced by chronic decrease in blood flow are endothelium-dependent. Science 1986; 231: 405-407
29. Rudic RD, Shesely EG, Nobuyo M et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101: 731-736
30. Tronc F, Wassef M, Esposito B et al. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996; 16: 1256-1262
31. Yogo K, Shimokawa H, Funakoshi H et al. Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol 2000; 20: E96-E100
32. Schoenhagen P, Ziada KM, Kapadia SR et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101: 598-603
33. Dimmeler S, Rippmann V, Weiland U et al. Angiotensin II induces apoptosis of human endothelial cells - protective effect of nitric oxide. Circ Res 1997; 81: 75-83
34. Asai K, Kudej RK, Shen YT et al. Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. Arterioscler Thromb Vasc Biol 2000; 20: 1493-1499
35. Dimmeler S, Haendeler J, Rippmann V et al. Shear stress inhibits apoptosis of human endothelial cells. FEBS Lett 1996; 399: 71-74
36. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-670
37. Fuster V, Badimon L, Badimon JJ et al. The pathogenesis of coronary artery disease and the acute coronary syndrome (2). N Engl J Med 1992: 326: 310-318
38. Britten MB, Schächinger V. Bedeutung der Endothelfunktion für die ischämische Manifestationen der koronaren Atherosklerose [Role of endothelial function for ischemic manifestation of coronary artery disease]. Herz 1998; 23: 97-105
39. Tomai F, Crea F, Gaspardone A et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2001; 104: 1471-1476
40. Mallat Z, Benamer H, Hugel B et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843
41. Zeiher AM, Schächinger V, Weitzel SH et al. Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. Circulation 1991; 83: 1519-1525
42. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906
43. Bauersachs J, Bouloumie A, Mulsch A et al. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res 1998; 37: 772-779
44. Al Suwaidi J, Hamasaki S, Higano ST et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954
45. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678
46. Schächinger V. Therapeutische Optionen zur Verbesserung der Myokardperfusion bei koronarer Atherosklerose [Therapeutic options to improve myocardial perfusion in coronary atherosclerosis]. Herz 1998; 23: 116-129
47. Maron DJ, Fazio S, Linton MF. Current perspective on statins. Circulation 2000; 101: 207-213
48. Laufs U, La FV, Plutzky J et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135
49. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation 1997; 95: 1126-1131
50. Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-1935
51. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J A M A 1998; 279: 1643-1650
52. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-328
53. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844
54. Diet F, Pratt RE, Berry GJ et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1997; 94: 2756-2767
55. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378
56. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-1118
57. Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258-265
58. 15O]water dobutamine stress positron emission tomography. J Am Coll Cardiol 1999; 34: 1005-1011
59. Soejima H, Ogawa H, Yasue H et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999; 34: 983-988
60. Napoleone E, Di Santo A, Camera M et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000; 86: 139-143
61. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
62. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
63. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010
64. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160
65. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (Vitamin C) and alpha-tocopherol (Vitamin E). Circ Res 2000; 87: 349-354
66. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J A M A 1998; 280: 605-613
67. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J A M A 2002; 288: 321-333
68. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J A M A 2002; 288: 49-57
69. Ridker PM, Hennekens CH, Rifai N et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-716
70. Schächinger V, Zeiher AM. Prognostic implications of endothelial dysfunction: does it mean anything? Coron Artery Dis 2001; 12: 435-443
71. Fichtlscherer S, Rossig L, Breuer S et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001; 104: 3023-3025
72. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-222
73. Kullo IJ, Mozes G, Schwartz RS et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation 1997; 96: 2254-2261
74. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779
75. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634-637
76. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436